Enliven Therapeutics ELVN Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's cash ratio?
- Enliven Therapeutics (ELVN) reported cash ratio of 11.5× in Q1 2026.
- How has Enliven Therapeutics's cash ratio changed year-over-year?
- Enliven Therapeutics's cash ratio increased by 58.1% year-over-year, from 7.3× to 11.5×.
- What is the long-term trend for Enliven Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), Enliven Therapeutics's cash ratio has grown at a -4.8% compound annual growth rate (CAGR), from 7.6× to 6×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.